130 results about "Catenin" patented technology

The invention provides a nerve growth factor functionalized exosome as well as a preparation method and application thereof. The functionalized exosome can activate a Wnt / beta-catenin signal channel to maintain dryness of corneal limbal stem cells (LSCs) so as to promote corneal epithelium repair, can activate a cAMP signal channel to relieve inflammatory response and promote corneal nerve regeneration, and can be used for treating or relieving corneal chemical burns, including relieving inflammatory response, reducing stromal scar formation and inhibiting corneal neovascularization. Corneal epithelium repair and nerve regeneration are promoted.

The present invention relates to use of a JWA polypeptide in the preparation of a drug for resisting androgenetic alopecia. An amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an amino acid S is subjected to phosphorylation modification, and X and Z are an amino acid or an amino acid sequence, respectively. The described JWA polypeptide can directly target integrin molecules onto hair follicle cells and enter the cells to play a role in regulating and controlling hair follicle proliferation, promoting hair growth and the like; the telogen phase of the hair follicles is significantly shortened, and the anagen phase of the hair follicles is prolonged; the hair shaft and follicle volume is increased; and the expression level of the target cell integrin molecule αvβ1 can be improved, and the hair follicle stem cell signal channel MEK / ERK / E2F1 / SP1 / Wnt10a / 10b / β-catenin can be accurately activated.

The invention belongs to the technical field of gene engineering, and particularly relates to a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of AML patients and application of ubiquitin specific protease 20 serving as a target spot in treating acute myelogenous leukemia. The invention provides a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of an AML patient and application of ubiquitin specific protease 20 as a target spot in treating acute myelogenous leukemia, USP20 is used as a super enhancer regulation gene, and the progress of the AML is promoted by combining with CTNNB1, ERG, ELF1 and RUNX1. The knock-down of the USP20 can significantly inhibit AML proliferation in vivo and in vitro. The wnt-beta-catenin pathway can be influenced by interfering the expression of the USP20 so as to influence the progress of AML (acute myeloid leukemia). And the inhibition effect of the inhibitor AS1517499 subjected to virtual screening on the growth of the AML cells is superior to that of a commercial inhibitor GSK2643943A of USP20.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention provides application of an RBM39 inhibitor in preparation of beta-catenin mutation liver cancer prevention and treatment products, and belongs to the technical field of beta-catenin mutation liver cancer prevention and treatment drugs. The invention provides an application of RBM39 as a target spot in preparation of a beta-catenin mutation liver cancer prevention and treatment product, and an application of an RBM39 inhibitor in preparation of a beta-catenin mutation liver cancer prevention and treatment product. Tests prove that the RBM39 inhibitor can effectively delay the occurrence and development of the beta-catenin mutant liver cancer in vivo, and the targeted therapy problem of the beta-catenin mutant liver cancer is solved.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The application discloses a kind of small molecule compound combination and the method for preparing vascular endothelial cell using the small molecule compound combination induced differentiation cell.The method is directed to induce differentiated cell, and finally prepare vascular endothelial cell;The directional induction includes inhibiting the activity of lysine deacetylase, inhibiting the signal path of TGF-β, inhibiting the activity of DNA methyltransferase (DNMT), activating the signal path of WNT / β-catenin and activating the signal path of cAMP.The present application can be converted into vascular endothelial cell by small molecule compound combination induction, and each step can realize accurate quality control, which is convenient for standardized operation and large-scale production.The method provided by the present application has wide donor sources, and the patient himself can be used as a donor, so that the vascular endothelial cells required for basic research, clinical treatment or tissue engineering production can be obtained in a short time.

The present invention relates to a peptide with the activity of promoting hair growth or preventing or inhibiting alopecia. The peptide of the present invention promotes the proliferation of human follicular dermal papilla cells (HFDPC), activates cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhances the expression levels of beta-catenin downstream genes, down-regulates the expression levels of the hair loss protein DKK-1, increases the expression of keratin proteins in hair outer root sheath cells (HORSC) and up-regulates the expression of transcription factors involved in cell activation in germinal matrix cells (GMC).

The invention belongs to the technical field of bioengineering, and discloses a UBXN10 active polypeptide, a carrier thereof and application of the UBXN10 active polypeptide in anti-cancer drugs. The amino acid sequence of the UBXN10 active polypeptide is as shown in SEQ ID NO: 1, and the nucleotide sequence for coding the UBXN10 active polypeptide is as shown in SEQ ID NO: 2. According to the invention, a plurality of functional means are utilized to analyze the transcriptional activity of cancer promoting beta-catenin in colorectal cancer cells and the antagonism of cancer cell proliferation and stem cell nature. The cell biology level proves that the UBXN10 active polypeptide has the potential of antagonizing beta-catenin mediated proliferation and stem cell gene expression and inhibiting colorectal cancer cell proliferation and stem cell property.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The invention relates to the technical field of biological medicine, in particular to a fibroblast-targeting phycocyanin conjugate, a sol preparation and application of the fibroblast-targeting phycocyanin conjugate, phycocyanin and targeting peptide are covalently linked through an SMCC cross-linking agent, LDL receptor-associated protein 1 highly expressed by fibroblast is specifically recognized through the targeting peptide, and efficient intracellular delivery is achieved; a water-soluble sol preparation carries phycocyanin to break through a cell barrier, and LRP1-rich fibroblasts in a wound are targeted and play a role in the fibroblasts. By inhibiting the EMT process of fiber cells, cell fibrosis and growth of wound bacteria are inhibited, scar formation is reduced, and wound healing is promoted. The defect that natural phycocyanin cells are poor in penetrability is overcome, scar-free healing is achieved by regulating Wnt5a / beta-catenin through targeted delivery, the effect is good, and application and popularization are convenient.

The invention relates to hair-blacking essence and a preparation method thereof. Screening a symbiotic bacterium metabolism extract with small molecule peptide metabolism regulation capability; by combining low-concentration azelaic acid and zinc lactate components, scalp grease oxidation and abnormal proliferation of propionibacterium are inhibited; the expression of IL-10 anti-inflammatory factors is induced, the expression of TNF-alpha and IL-6 is reduced, and the hair follicle microinflammation state is reduced; a Wnt / beta-catenin pathway activator is used for inducing the melanin stem cells to be in a static state; the FGF-2 and the EGF are combined in a micro-dose manner to promote the amplification into precursor cells; mITF regulation peptides and a small amount of trace copper ions are supplemented to induce directional differentiation into mature melanocytes; a microcapsule carrier system with a three-layer structure; the penetration efficiency is improved; antioxidative peptide rich in reduced glutathione, NAD and a promoting factor are used, so that melanocytes are protected from oxidative damage; a coenzyme Q10 type mitochondrial homeostasis regulator is introduced, so that the energy metabolism is improved, the cell aging is delayed, the targeting property is strong, and the effect is accurate.

The invention provides a high-transparency and high-simulation bacterial engineering biological cornea as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering cornea materials. According to the method, a bacterial synthetic biology method is adopted, a curvature customization model and an hydroformylation system are combined, and the high-transparency bionic cornea (DBC-L-Cel) which is customized in curvature and shape and has a nanofiber network structure is constructed. The light transmittance of the bionic cornea reaches 91.91%, the light transmittance and the mechanical property of the bionic cornea are matched with those of a natural cornea, and meanwhile the bionic cornea has excellent biocompatibility, adhesiveness and scar resistance. In-vitro experiments show that DBC (at) L-Cel can reduce matrix fibrosis by inhibiting AGE / RAGE / NF [kappa] B and PI3K / AKT pathways and up-regulate Wnt / beta-catenin pathway to activate proliferation, and corneal epithelium is repaired by an adhesion function. In-vivo experiments show that the high-simulation biological cornea DBC-L-Cel is transplanted to a rabbit model with large-scale corneal defects, repair and regeneration of corneal stroma and epithelium can be remarkably promoted, and rapid scar-free repair and reconstruction of the damaged cornea are achieved.

The invention discloses a sterone compound derived from achyranthes bidentata as well as a preparation method and application of the sterone compound. Belongs to the technical field of biological medicine. The invention aims to solve various side effects and defects of the existing medicine for treating glucocorticoid-induced osteoporosis in long-term use. The molecular formula of the compound (SSA) is C33H48O9, the compound (SSA) has a beta-ecdysterone skeleton, and acetal type 5-hydroxymethylfurfural groups are introduced at the positions of side chains C20 and C22. SSA has a remarkable protection effect in a DEX-induced osteoblast injury model, can improve cell viability decline and G1 phase retardation caused by glucocorticoid, and recovers osteogenic differentiation and mineralization ability. The SSA effectively reverses the inhibition effect of DEX on osteoblasts by activating a Wnt / beta-catenin signal channel and up-regulating the expression of RUNX2. SSA has a remarkable anti-osteoporosis function potential.

The invention provides a polypeptide for enhancing T cell function and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the polypeptide disclosed by the invention is as shown in SEQ ID NO. 1. According to the invention, an interaction interface of CLDN18.2 and beta-catenin is targeted for the first time, the full D-type functional polypeptide is designed to realize high-stability and high-affinity protein-protein interaction blocking, and the problem that the interaction site is difficult to target by the traditional antibody drug or small molecule drug is broken through; the used polypeptide PC18.1 has good in-vitro stability and is suitable for subsequent clinical development; the polypeptide is easy to prepare on a large scale through a synthesis means, has the purity of more than or equal to 98%, is low in cost and convenient to modify, and can be flexibly applied to immune combined treatment schemes such as nano-carrier loading and local delivery.

The application provides a kind of nasal mucosa in vitro culture method and culture fluid, the composition of the culture fluid includes Wnt / β-catenin signal pathway activator 0.1-20 μg / ml, fibroblast growth factor 10-150 ng / ml, TGF-β inhibitor 0.02-3 μg / ml, ROCK inhibitor 0.1-100 μmol / L, P38 MAPK inhibitor 0.1-1 μmol / L, serum-free additive 1X, N-acetyl cysteine 1-10 mmol / L, nicotinamide 1-20 mmol / L, GlutaMax additive 1X, antibiotic, DMEM / F12 culture medium 1X.The application can carry out in vitro culture to nasal mucosa, can keep at least 2 weeks of activity, and have complete epithelial barrier and immune system, can realize ex vivo nasal mucosa virus infection experiment.

This invention provides the application of the IFI16 gene as a target in the preparation of bortezomib-resistant drugs for the treatment of multiple myeloma, involving drug targets, related diagnostic reagents, and treatment strategies for the diagnosis and treatment of multiple myeloma (MM). This invention reveals for the first time the core driving role of IFI16 in bortezomib resistance in MM and its novel mechanism of action through the Wnt / β-catenin pathway; more importantly, it provides novel biomarkers, drug targets, and highly feasible combination therapy regimens for accurate prognostic assessment of MM and overcoming the clinically challenging problem of bortezomib resistance, possessing significant theoretical implications and broad clinical application prospects.

The invention relates to the field of oncology, in particular to application of a cancer immunotherapy target and a diagnosis and prognosis prediction biomarker. Wherein at least one marker in the EGFR / Wnt / beta-catenin-LINC00973-miRNA-CD55 / CD59 pathway can be used for evaluating the sensitivity or the prognosis of the cancer immunotherapy.

The present invention provides a method for administering a β-catenin peptide antagonist, and a method for treating solid tumors by administering a β-catenin peptide antagonist.

The present invention relates to a method for preparing fluorescent carbon dots and their application, belonging to the field of new materials. The present invention provides a method for synthesizing fluorescent carbon dots in one step by microwave method using the Chinese medicinal material Aucklandia lappa as a carbon source. The method is simple, economical, and environmentally friendly. The prepared fluorescent carbon dots have excellent fluorescence properties, with a maximum excitation wavelength of 360 nm and a maximum emission wavelength of 465 nm. The present invention uses fluorescent carbon dots to develop a new type of fluorescent chemical sensor for rapid, highly sensitive, and highly selective detection of Fe 3+ The linear range is 0.2-200 μmol / L, and the detection limit is as low as 62 nmol / L. This method shows good recovery and reproducibility in actual water sample detection, which is a good indicator of Fe 3+ The detection of β-catenin provides a simple and efficient new approach with broad application prospects.

The present disclosure relates to antibodies directed against beta-catenin and formulations comprising the same. The disclosure further relates to the use of beta-catenin antibodies and formulations in therapy, particularly in the treatment of solid tumors.

The invention relates to the field of biological medicines, in particular to application of fatty acid synthase (FASN) as a target spot in screening or preparing medicines for treating breast cancer, and particularly relates to targeted therapy for breast cancer stem cells (BCSCs). The invention discloses application of an FASN target spot in screening or preparing a medicine for treating breast cancer. Research finds that FASN is highly expressed in BCSCs, and stem cell characteristics of the BCSCs are maintained by activating a Wnt / beta-catenin pathway. By inhibiting the activity of FASN (such as using lansoprazole), the proliferation, self-renewal and tumor formation ability of BCSCs can be significantly reduced. The invention provides an FASN-based drug screening method and a drug composition, and provides a new strategy for breast cancer treatment.

This specification provides peptides that bind to β-catenin and compositions comprising such peptides. Agents utilizing peptides that directly bind to β-catenin can be used for imaging, diagnosis, and treatment of diseases caused by β-catenin dysfunction. This specification also provides methods for using such peptides and compositions in imaging, diagnosis, and treatment of tissue-invasive diseases, including endometriosis.

The invention provides a hair growth composition or a pharmaceutical composition containing rutin and application of rutin in preparation of the hair growth composition or the pharmaceutical composition. The invention provides application of rutin in improvement of hair growth and prevention of alopecia. The rutin can improve hair growth and prevent alopecia by activating a Wnt / beta-catenin signal channel, promoting proliferation of human dermal papilla cells and promoting growth of hair follicles.

The invention discloses a special culture medium for enriching primary lung cancer stem cells and a cell culture and identification method, the cell culture medium is composed of a basic culture medium, a nutrient source, a pathway activation / inhibition component, an antioxidant component, an anti-apoptosis component, a proliferation promoting component and a cell differentiation related component, and the culture medium takes advanced DMEM / F12 as the basic culture medium. A serum-free cell culture additive in the cell culture medium improves the universality of the cell culture medium to lung cancer cells, Wnt / beta-catenin signals are amplified by a Wnt signal enhancer R-Spondin3 to maintain the characteristics of stem cells, proliferation and survival of the stem cells are jointly promoted by EGF, bFGF and vitamin B3 derivative Nicotinamide, cell apoptosis is inhibited by an ROCK inhibitor Y-27632 and EGF, and the cell culture medium is used for treating lung cancer cells. The TGF-beta receptor inhibitor A83-01 and the bFGF are used for inhibiting cell differentiation signals and maintaining the state of stem cells / progenitor cells, the antioxidant B27 and the N-Acetyl Cysteine are used for preventing oxidative stress damage and maintaining downward survival, and the proportion of all the components in the cell culture medium is adjusted.

The invention belongs to the technical field of protein engineering, and discloses a humanized collagen XVII type polypeptide as well as a preparation method and application thereof. The amino acid sequence of the humanized collagen XVII type polypeptide is as shown in SEQ ID NO.1, and the polynucleotide sequence for coding the humanized collagen XVII type polypeptide is as shown in SEQ ID NO.2. The invention also provides application of the polypeptide in preparation of a protein product with functions of preventing hair loss and growing hair and / or repairing, resisting wrinkles and tightening skin. The application proves that the humanized collagen XVII type polypeptide can promote proliferation of hair papilla cells, keratinocytes and fibroblasts and promote up-regulation of expression of beta-Catenin signal channel protein closely related to hair growth in the hair papilla cells; the up-regulation expression of fibroblast type III collagen, type IV collagen, type VII collagen, fibronectin and elastin is promoted, so that the polypeptide is proved to have the effects of preventing hair loss and growing hair and / or repairing, resisting wrinkles and tightening skin.

A culture medium for immune cells and use thereof. The culture medium comprises: 200-1000 U / mL IL-2, 10-100 ng / mL IL-4, 10-100 ng / mL IL-15, 2-20 ng / mL anti-CD3 monoclonal antibody, 2-20 ng / mL anti-CD28 monoclonal antibody, 0.5-20 μM GSK-3β inhibitor, 0.1-10 μM Wnt / β-catenin signaling pathway agonist, 1-10 μg / mL transferrin, 1-10 μg / mL ethanolamine, 1-10 μg / mL water-soluble cholesterol, 1-10 μg / mL insulin, 1-10 mM L-alanyl-L-glutamine, 1-10 μg / mL L-ascorbic acid, 1-10 μg / mL taurine, 0.1-1 μg / mL putrescine, and an RPMI 1640 medium. The culture medium can effectively keep the survival rate of cells, efficiently induce the proliferation of memory T cells, and amplify the number of memory T cells. The culture medium has the advantages of low cell culture cost and good cell quality.

Provided herein are compounds that are useful for or methods of inhibiting β-catenin or disrupting the interaction between β-catenin and T-cell factor 4, which are useful in the treatment of diseases or health conditions, such as cancer, neurodegenerative, a metabolic disease, a cardiovascular disease, fibrosis, and a bone disease. In one aspect, the compounds have Formula 1 wherein R1 is —(CR42)mXR5; R2 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, aralkyl, heteroaralkyl, or heteroaryl; and R3 is —(CR62)nR7.

The present application provides a kind of human umbilical cord mesenchymal stem cell secretory exosome and anti-aging essence based on the exosome and its preparation method and application.By activating Wnt / β-catenin signaling pathway, the yield of exosome and the secretion amount of miR-21 are significantly improved, and the purity and biological activity of exosome are effectively purified by using microfluidic technology. The essence formula contains exosome, HA-Lipo composite carrier, asiaticoside microspheres and dipropylene glycol, and has good skin repair and anti-aging effect. Animal experiments have verified that the essence of the present application can effectively improve skin wrinkles, epidermal thickness and skin barrier function in UVB-induced skin photoaging model, and its molecular mechanism is related to the regulation of collagen metabolism. The essence has significant application prospect in the field of skin beauty and anti-aging.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.